STOCK TITAN

Vanguard realigns reporting; Axogen (NASDAQ: AXGN) shows 0 shares owned

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

The Vanguard Group files an amendment to Schedule 13G disclosing zero beneficial ownership of Axogen Inc common stock. The filing states an amount beneficially owned: 0 and percent of class: 0%. It explains an internal realignment adopted on 01/12/2026 that prompted disaggregated reporting by certain Vanguard subsidiaries.

Positive

  • None.

Negative

  • None.

Insights

Vanguard disaggregated holdings and reports no beneficial ownership of Axogen common stock.

The filing lists amount beneficially owned: 0 and percent of class: 0%, reflecting reporting changes after an internal realignment dated 01/12/2026. This is a reporting adjustment rather than a market trade.

Cash-flow treatment and any prior holdings are not stated in the excerpt; subsequent filings may provide additional ownership detail.

Amendment shows disaggregated reporting by Vanguard entities under SEC Release No. 34-39538.

The amendment explains that certain subsidiaries will report separately and that Vanguard "no longer has, or is deemed to have, beneficial ownership" over those subsidiaries' securities per the cited SEC release.

This is a procedural disclosure about beneficial ownership attribution; it does not by itself indicate a change in Axogen's governance or capital structure.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026

FAQ

What did The Vanguard Group report for AXGN in this Schedule 13G/A amendment?

The filing reports 0 shares beneficially owned and 0% of the class. It states Vanguard disaggregated holdings following an internal realignment on 01/12/2026, leading subsidiaries to report separately under SEC Release No. 34-39538.

Does the amendment state Vanguard sold Axogen (AXGN) shares?

No—this amendment describes reporting changes and lists amount beneficially owned: 0. It does not state any specific sale transactions or transfer of economic interest in the excerpt provided.

Why does Vanguard say it now reports holdings separately for AXGN?

The filing cites an internal realignment on 01/12/2026 and relies on SEC Release No. 34-39538 to disaggregate subsidiaries or business divisions that formerly reported under The Vanguard Group, Inc.

Who signed the Schedule 13G/A amendment for Vanguard regarding AXGN?

The amendment is signed by Ashley Grim, identified as Head of Global Fund Administration, with the signature date shown as 03/26/2026 in the excerpt.

Does the filing disclose any shares held on behalf of other persons for AXGN?

The filing states Vanguard and its managed accounts have the right to receive dividends or proceeds, and it discloses that no other single person's interest reported exceeds 5% of the class based on the excerpt.
Axogen Inc

NASDAQ:AXGN

View AXGN Stock Overview

AXGN Rankings

AXGN Latest News

AXGN Latest SEC Filings

AXGN Stock Data

1.62B
49.75M
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
ALACHUA